Table 5.
Outcomes in the Matched-Cohort
| Low/Intermediate risk | High risk | Very high risk | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CS, N=65 | CS+TCZ, N=54 | p value | CS, N=542 | CS+TCZ, N=554 | p value | CS, N=257 | CS+TCZ, N=238 | p value | |
| In-hospital death | 1 (1.5) | 4 (7.4) | 0.175 | 125 (23.1) | 111 (20) | 0.223 | 82 (31.9) | 57 (23.9) | 0.049 |
| HFNC | 3 (4.6) | 16 (29.6) | <0.001 | 87 (16.1) | 156 (28.2) | <0.001 | 50 (19.5) | 74 (31.1) | 0.003 |
| NIMV | 1 (1.5) | 10 (18.5) | 0.002 | 57 (10.5) | 103 (18.6) | <0.001 | 34 (13.2) | 39 (16.4) | 0.322 |
| IMV | 2 (3.1) | 9 (16.7) | 0.022 | 75 (13.8) | 123 (22.2) | <0.001 | 46 (17.9) | 68 (28.6) | 0.005 |
| ICU | 4 (6.2) | 11 (20.4) | 0.026 | 102 (18.8) | 168 (30.3) | <0.001 | 59 (23) | 84 (35.3) | 0.002 |
| Length of stay (days), median [IQR] | 8 [4.5–12] | 12 [8–18.5] | 0.001 | 10 [6.8–16] | 14 [10–20] | <0.001 | 11 [6–20] | 15 [10–23] | <0.001 |
HFNC high-flow nasal cannula, NIMV non-invasive mechanical ventilation, IMV invasive mechanical ventilation, ICU intensive care unit, IQR interquartile range, CS corticosteroids, CS+TCZ corticosteroids + tocilizumab